Please try another search
Arch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada. It focuses on developing its lead drug candidate LSALT Peptide, a product in Phase 2 clinical trials to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys. The company also develops AB569 for treating antibiotic-resistant bacterial infections, and for the treatment of wounds; and Borg, a peptide-solid surface interface to reduce corrosion of metals. Arch Biopartners Inc. is based in Toronto, Canada.
Name | Age | Since | Title |
---|---|---|---|
Claude Allary | 68 | 2012 | Independent Director |
Robert Hodges | - | - | Member of Scientific Advisory Board |
Hindrik Mulder | - | - | Member of Scientific Advisory Board |
Richard Rossman | 78 | 2010 | Independent Director |
Daniel Abraham Muruve | - | 2011 | Co-Founder, Chief Science Officer & Member of Scientific Advisory Board |
Andrew Bishop | 58 | 2010 | CFO & Director |
Richard Gabriel Muruve | 53 | 2005 | Co-Founder, CEO, President & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review